IBDEI0DI ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6199,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,6199,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,6199,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,6200,0)
 ;;=E83.51^^30^388^28
 ;;^UTILITY(U,$J,358.3,6200,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6200,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,6200,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,6200,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,6201,0)
 ;;=E83.52^^30^388^26
 ;;^UTILITY(U,$J,358.3,6201,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6201,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,6201,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,6201,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,6202,0)
 ;;=E87.5^^30^388^27
 ;;^UTILITY(U,$J,358.3,6202,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6202,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,6202,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,6202,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,6203,0)
 ;;=E89.2^^30^388^48
 ;;^UTILITY(U,$J,358.3,6203,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6203,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,6203,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,6203,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,6204,0)
 ;;=E89.6^^30^388^47
 ;;^UTILITY(U,$J,358.3,6204,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6204,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,6204,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,6204,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,6205,0)
 ;;=L68.0^^30^388^25
 ;;^UTILITY(U,$J,358.3,6205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6205,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,6205,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,6205,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,6206,0)
 ;;=M80.00XA^^30^388^2
 ;;^UTILITY(U,$J,358.3,6206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6206,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,6206,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,6206,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,6207,0)
 ;;=M81.0^^30^388^3
 ;;^UTILITY(U,$J,358.3,6207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6207,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,6207,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,6207,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,6208,0)
 ;;=M85.80^^30^388^44
 ;;^UTILITY(U,$J,358.3,6208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6208,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,6208,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,6208,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,6209,0)
 ;;=N62.^^30^388^24
 ;;^UTILITY(U,$J,358.3,6209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6209,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,6209,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,6209,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,6210,0)
 ;;=E10.43^^30^388^6
 ;;^UTILITY(U,$J,358.3,6210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6210,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,6210,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,6210,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,6211,0)
 ;;=E10.59^^30^388^4
 ;;^UTILITY(U,$J,358.3,6211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6211,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,6211,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,6211,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,6212,0)
 ;;=E10.618^^30^388^5
 ;;^UTILITY(U,$J,358.3,6212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6212,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,6212,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,6212,2)
 ;;=^5002614
